Scroll to Top

Volume : V, Issue : X, November - 2015

EXPRESSION OF HER2 AND TOPOII ALPHA IN BREAST CANCER

Diab,M., Shaker,O.; Nassar, Y.; Abd El-Aziz,G. and El-Marzoki,M.

By : Laxmi Book Publication

Abstract :

Background: In breast cancer (BC) overexpression of some oncogenes as Human epidermal growth factor receptor and Topoisomerase IIA has been shown to play an important role in the development and progression of certain aggressive types. In recent years these proteins have become an important biomarkers. Objective: The aim of this study was to detect the expression of Her2 and TopoIIA genes in both metastatic and non-metastatic groups of cancer breast patients.

Keywords :


Article :


Cite This Article :

Diab,M., Shaker,O.; Nassar, Y.; Abd El-Aziz,G. and El-Marzoki,M.(2015). EXPRESSION OF HER2 AND TOPOII ALPHA IN BREAST CANCER. Indian Streams Research Journal, Vol. V, Issue. X, http://isrj.org/UploadedData/7367.pdf

References :

  1. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  2. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  3. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  4. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  5. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  6. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  7. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  8. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  9. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  10. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  11. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  12. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  13. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  14. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  15. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  16. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  17. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  18. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  19. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  20. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  21. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  22. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  23. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  24. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  25. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  26. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  27. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  28. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  29. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  30. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  31. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  32. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  33. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  34. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  35. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  36. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  37. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  38. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  39. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  40. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  41. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  42. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  43. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  44. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  45. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  46. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  47. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  48. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  49. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  50. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  51. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  52. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  53. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  54. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  55. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  56. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  57. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  58. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  59. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  60. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  61. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  62. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  63. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  64. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  65. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  66. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  67. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  68. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  69. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  70. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  71. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  72. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  73. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  74. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  75. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  76. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  77. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  78. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  79. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  80. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  81. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  82. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  83. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  84. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  85. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  86. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  87. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  88. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  89. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.
  90. Coon, J.S., Marcus, E. and Gupta-Burt, S. 2002. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067.
  91. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  92. Foulkes, W., and Narod, S. 1995. Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing. Clin.Invest. Med., 18: 473-483.
  93. Gianni, L., Dafni, U. and Gelber, R.D. (2011): Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with Her2.positive early breast cancer: a 4year follow up of a randomised controlled trial. Lancet Oncol 12: 236-244.
  94. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA., 104: 11014-11019.
  95. Depowski, S.L., Rosenthal, T.M., Brien, S., Stylis, R.L., Johnson and J.S. Ross 2000. Topoisomerase 2 alpha expression in breast cancer: correlation with clinical variables, Mod Pathol., 13: 542-547.

Article Post Production

    No data exists for the row/column.
Creative Commons License
Indian Streams Research Journal by Laxmi Book Publication is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://oldisrj.lbp.world/Default.aspx.
Permissions beyond the scope of this license may be available at http://oldisrj.lbp.world/Default.aspx
Copyright � 2014 Indian Streams Research Journal. All rights reserved
Looking for information? Browse our FAQs, tour our sitemap, or contact ISRJ
Read our Privacy Policy Statement and Plagairism Policy. Use of this site signifies your agreement to the Terms of Use